

Integrated DNA Technologies (IDT) – Fact Sheet

About IDT

- IDT, an operating company within Danaher Corporation's (NYSE: DHR) Life Sciences platform, is headquartered in Coralville, Iowa and has been a leader in life sciences for more than 30 years
- IDT leads the industry in the manufacture of custom oligonucleotides for molecular biology applications. IDT has also developed proprietary technologies for genomics applications, such as Next Generation Sequencing, CRISPR genome editing, qPCR, and RNA interference.
- IDT serves more than 120,000 life sciences researchers in more than 100 countries.
- IDT has more than 1,400 employees worldwide.
- Our recent history includes providing products to diagnostic test manufacturers developing tests for H1N1, Ebola virus, and Zika virus.
- IDT has already shipped synthetic genes for use in the pursuit of coronavirus vaccines, as well as customized oligonucleotide probes and primers that will facilitate more sensitive and accurate detection of 2019-nCoV/SARS-CoV-2.

IDT's COVID-19 Response

- On January 28, 2020, IDT announced it was accepting pre-orders from the global public health and research communities for qPCR primers and probes designed to aid researchers in the detection of 2019-nCoV. IDT started fulfilling orders on February 10th.
- The primer and probe kits are manufactured in IDT's Coralville, Iowa headquarters. The primer and probe kits are manufactured under ISO 13485:2016 conditions in a suite of cleanrooms designed to prevent synthetic template contamination. The primer and probe kits are formulated to meet CDC's recommended primer-to-probe ratio.
- IDT primer and probe kits are a key component of the CDC testing protocol for which the CDC obtained Emergency Use Authorization (EUA) for the diagnosis and detection of COVID-19.
- The CDC and FDA first contacted IDT on February 25th to discuss its ability to support the CDC EUA testing protocol. IDT shipped primer and probe kits to the CDC the same day for delivery on February 26th. On March 2nd, the FDA included IDT lot#0000500383 as the first lot of primers and probe kits in the US qualified under the CDC's EUA. Subsequently, the CDC has continued to qualify additional lots of IDT primer and probe kits. Current information on qualified lots is available on the IDT website.

GLOBAL HEADQUARTERS

Integrated DNA Technologies, Inc.
1710 Commercial Park
Coralville, IA 52241
USA

> WWW.IDTDNA.COM

- As of March 9th, IDT has manufactured, and CDC has qualified, primer and probe kits sufficient to enable over one million tests pursuant to the CDC EUA testing protocol. IDT expects to manufacture sufficient primer and probe kits to enable 2.5 million tests the week of March 9th, and five million tests per week starting March 16th, and thereafter.
- The CDC EUA testing protocol for the diagnosis and detection of COVID-19 requires special testing equipment and is not a direct to consumer test. IDT's primer and probe kits are made available to the CDC and other qualified institutions who carry out disease diagnosis as a routine matter of their business. These tests require specific equipment and consumable reagents in order to complete the testing.

Media Contacts

IDT Public Relations, idtpr@idtdna.com

Anna Blyth, ablyth@apcoworldwide.com

Iris Shaffer, ishaffer@apcoworldwide.com

**As of March 16, 2020*

GLOBAL HEADQUARTERS

Integrated DNA Technologies, Inc.
1710 Commercial Park
Coralville, IA 52241
USA

> WWW.IDTDNA.COM